Gilotrif Tablet, Film Coated
NDC Package 0597-0141-30
Package Information
Gilotrif (afatinib) tablets is afatinib is used to treat a certain type of lung cancer (non-small cell lung cancer). This formulation utilizes a tablet, film coated delivery system. Marketed by Boehringer Ingelheim Pharmaceuticals, Inc., this product is identified by NDC 0597-0141 and is authorized under FDA application NDA201292.
Identification & Billing
- RxCUI: 1430446 - afatinib 20 MG Oral Tablet
- RxCUI: 1430446 - afatinib 20 MG (as afatinib dimaleate 29.56 MG) Oral Tablet
- RxCUI: 1430449 - Gilotrif 20 MG Oral Tablet
- RxCUI: 1430449 - afatinib 20 MG Oral Tablet [Gilotrif]
- RxCUI: 1430449 - Gilotrif 20 MG (as afatinib dimaleate 29.56 MG) Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0597 - Boehringer Ingelheim Pharmaceuticals, Inc.
- 0597-0141 - Gilotrif
- 0597-0141-30 - 1 BOTTLE in 1 CARTON / 30 TABLET, FILM COATED in 1 BOTTLE
- 0597-0141 - Gilotrif
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0597-0141-30 identifies a specific commercial package of 1 bottle in 1 carton / 30 tablet, film coated in 1 bottle of Gilotrif, a human prescription drug labeled by Boehringer Ingelheim Pharmaceuticals, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This tablet, film coated is formulated for oral use and contains afatinib as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Boehringer Ingelheim Pharmaceuticals, Inc. on July 12, 2013. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Afatinib is used to treat a certain type of lung cancer (non-small cell lung cancer). It belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors.
How is this Boehringer Ingelheim Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00597014130. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.